Loading
Every dated change on the records linked to HER2-positive breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Weight loss achieved; primary iDFS endpoint not met at first analysis (presented 2025; publication pending, verify).
3-year iDFS 92.
PFS HR 0.
pCR 67.
PFS 24.
PFS 30.
Five-year invasive disease-free survival 91.
Regional nodal irradiation after a complete nodal response to chemotherapy did not lengthen the invasive breast cancer recurrence-free interval (hazard ratio 0.
Implant loss 8.
Ten-year overall survival 81.
A milestone in how this cancer is treated.
PFS 11.
CNS ORR 71.
Ongoing; the first block results and de-escalation rates were reported from 2024.
Palbociclib added to maintenance anti-HER2 and endocrine therapy lengthened progression-free survival.
3-year iDFS 95.
Five-year recurrence-free survival 89.
A milestone in how this cancer is treated.
Ten-year axillary recurrence 1.
PFS 9.
Residual cancer removed by guided margins in 27 of 357 patients; per-margin specificity 85.
5-year DFS 86.
Five-year distant disease-free survival 98.
Very high three-year invasive disease-free survival with one year of trastuzumab emtansine in stage I disease, but clinically relevant toxicity was not lower than with paclitaxel plus trastuzumab.
PFS HR 0.
A milestone in how this cancer is treated.
HER2-positive metastatic breast cancer after chemotherapy, with vinorelbine
HER2+ metastatic breast cancer after ≥2 anti-HER2 regimens, with chemotherapy
At ten years, 28.
5-year ipsilateral breast tumour relapse 1.
Neratinib plus capecitabine improved progression-free survival over lapatinib plus capecitabine and reduced interventions for central nervous system disease; approved in February 2020.
Five-year local recurrence 2.
A milestone in how this cancer is treated.
OS 21.
Within three months of immediate implant-based reconstruction: implant loss 9 percent, infection needing treatment 25 percent, return to theatre 18 percent and readmission 18 percent, all above the National Quality Standards.
10-year ipsilateral breast tumour recurrence 4.
4-year DFS 89.
Eight-year ipsilateral breast tumour recurrence 3.
A milestone in how this cancer is treated.
HER2+ advanced breast cancer with capecitabine
Ten-year disease-free survival 76.
iDFS HR 0.
Pathological complete response 44.
At two years, autologous reconstruction gave higher satisfaction with breasts (7.
Pathological complete response 67% without anthracycline vs 68% with; 3-year event-free survival 93.
A milestone in how this cancer is treated.
Ten-year overall survival 86.
8-year iDFS HR 0.
5-year local relapse 0.
A milestone in how this cancer is treated.
Multiple graduations (veliparib-carboplatin, neratinib, pembrolizumab, MK-2206, T-DM1 plus pertuzumab, durvalumab plus olaparib, cemiplimab plus fianlimab); pembrolizumab's graduation preceded its approval in early triple-negative breast cancer.
Adding the clipped node to sentinel node dissection cut the false-negative rate from 10.
7-year DFS 93%; 10-year RFI 96.
Twenty-year ipsilateral breast recurrence 12.
10-year overall survival 82.
10-year disease-free survival 82.
A milestone in how this cancer is treated.
False-negative rate of sentinel node surgery after chemotherapy 12.
Ten-year local-regional relapse 6.
A milestone in how this cancer is treated.
At a median 22.
Pathological complete response and early MRI volume change predicted recurrence-free survival, most strongly in triple-negative, HER2-positive and MammaPrint high-risk tumours.
Pertuzumab added to trastuzumab and docetaxel raised the pathological complete response rate in HER2-positive breast cancer; neoadjuvant pertuzumab received accelerated approval in September 2013.
A milestone in how this cancer is treated.
B-31/N9831 10-year OS 84% vs 75.
A milestone in how this cancer is treated.
Twenty-year same-breast recurrence 8.
No significant difference in disease-free, relapse-free, distant-disease-free or overall survival between radical mastectomy, total mastectomy with irradiation and total mastectomy alone, at twenty-five years.
Twenty-year recurrence in the treated breast 14.